Literature DB >> 31068423

In Vivo Live Imaging of Oncolytic Mammalian Orthoreovirus Expressing NanoLuc Luciferase in Tumor Xenograft Mice.

Yuta Kanai1, Takahiro Kawagishi1, Yoshiharu Matsuura2, Takeshi Kobayashi3.   

Abstract

Wild-type mammalian reoviruses (MRVs) have been evaluated as oncolytic agents against various cancers; however, genetic modification methods for improving MRV agents have not been exploited fully. In the present study, using MRV strain T1L, we generated a reporter MRV that expresses a NanoLuc luciferase (NLuc) gene and used it for noninvasive imaging of MRV infection in tumor xenograft mice. NLuc and a P2A self-cleaving peptide gene cassette were placed upstream of the L1 gene open reading frame to enable bicistronic expression of NLuc and the L1 gene product. BALB/c nude mice intranasally infected with MRV expressing NLuc (rsT1L-NLuc) displayed bioluminescent signals in the chest area at 4 days postinfection (dpi), which is consistent with natural MRV infection in the lung. Furthermore, to monitor tumor-selective infection by MRV, nude mice bearing human cancer xenografts were infected intravenously with rsT1L-NLuc. Bioluminescent signals were detected in tumors as early as 3 dpi and persisted for 2 months. The results demonstrate the utility of an autonomous replicating reporter MRV for noninvasive live imaging of replicating oncolytic MRV agents.IMPORTANCE Engineering of recombinant MRV for improved oncolytic activity has not yet been achieved due to difficulty in generating autonomous replicating MRV harboring transgenes. Here, we constructed a reporter MRV that can be used to monitor cancer-selective infection by oncolytic MRV in a mouse model. Among the numerous oncolytic viruses, MRV has an advantage in that the wild-type virus shows marked oncolytic activity in patients without any notable adverse effects. The reporter MRV developed herein will open avenues to the development of recombinant MRV vectors armed with anticancer transgenes.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  cancer treatment; mammalian orthoreovirus; oncolytic virus; reporter virus

Mesh:

Substances:

Year:  2019        PMID: 31068423      PMCID: PMC6600198          DOI: 10.1128/JVI.00401-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector.

Authors:  Koji Ishii; Yoshiaki Ueda; Kazuhiro Matsuo; Yoshiharu Matsuura; Takashi Kitamura; Kenzo Kato; Yasuyuki Izumi; Kenji Someya; Takeaki Ohsu; Mitsuo Honda; Tatsuo Miyamura
Journal:  Virology       Date:  2002-10-25       Impact factor: 3.616

2.  Reovirus infections in human volunteers.

Authors:  L ROSEN; H E EVANS; A SPICKARD
Journal:  Am J Hyg       Date:  1963-01

3.  Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described.

Authors:  A B SABIN
Journal:  Science       Date:  1959-11-20       Impact factor: 47.728

4.  Reovirus as an oncolytic agent against experimental human malignant gliomas.

Authors:  M E Wilcox; W Yang; D Senger; N B Rewcastle; D G Morris; P M Brasher; Z Q Shi; R N Johnston; S Nishikawa; P W Lee; P A Forsyth
Journal:  J Natl Cancer Inst       Date:  2001-06-20       Impact factor: 13.506

5.  Oncolytic reovirus against ovarian and colon cancer.

Authors:  Kensuke Hirasawa; Sandra G Nishikawa; Kara L Norman; Tommy Alain; Anna Kossakowska; Patrick W K Lee
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

6.  Reovirus oncolysis of human breast cancer.

Authors:  Kara L Norman; Matthew C Coffey; Kensuke Hirasawa; Douglas J Demetrick; Sandra G Nishikawa; Lisa M DiFrancesco; James E Strong; Patrick W K Lee
Journal:  Hum Gene Ther       Date:  2002-03-20       Impact factor: 5.695

7.  Respiratory reovirus 1/L induction of diffuse alveolar damage: a model of acute respiratory distress syndrome.

Authors:  Lucille London; Elizabeth I Majeski; Manjeet Kaur Paintlia; Russell A Harley; Steven D London
Journal:  Exp Mol Pathol       Date:  2002-02       Impact factor: 3.362

8.  Reovirus reverse genetics: Incorporation of the CAT gene into the reovirus genome.

Authors:  M R Roner; W K Joklik
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

9.  Respiratory reovirus 1/L induction of intraluminal fibrosis, a model of bronchiolitis obliterans organizing pneumonia, is dependent on T lymphocytes.

Authors:  Elizabeth I Majeski; Manjeet K Paintlia; Andrea D Lopez; Russell A Harley; Steven D London; Lucille London
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

10.  Oncolytic viral therapy for human pancreatic cancer cells by reovirus.

Authors:  Tsuyoshi Etoh; Yoshihisa Himeno; Toshifumi Matsumoto; Masanori Aramaki; Katsunori Kawano; Akira Nishizono; Seigo Kitano
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

View more
  3 in total

1.  Generation of Genetically RGD σ1-Modified Oncolytic Reovirus That Enhances JAM-A-Independent Infection of Tumor Cells.

Authors:  Takahiro Kawagishi; Yuta Kanai; Ryotaro Nouda; Ichika Fukui; Jeffery A Nurdin; Yoshiharu Matsuura; Takeshi Kobayashi
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

2.  Reovirus: Friend and Foe.

Authors:  Michael R Eledge; Marcelle Dina Zita; Karl W Boehme
Journal:  Curr Clin Microbiol Rep       Date:  2019-07-04

3.  Recovery of NanoLuc Luciferase-Tagged Canine Distemper Virus for Facilitating Rapid Screening of Antivirals in vitro.

Authors:  Fuxiao Liu; Qianqian Wang; Yilan Huang; Ning Wang; Youming Zhang; Hu Shan
Journal:  Front Vet Sci       Date:  2020-12-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.